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Abstract
Background: Serum levels of CA125 measured before any treatment have been evaluated in epithelial ovarian
cancer (EOC) as a predictor of patient survival; however, results in survival index are controversial, as CA125 levels
are influenced by several variables. Taking this into consideration, the present study evaluated the association of
pretreatment levels of CA125 serum with the clinical stage, histology and differentiation grade of the tumor and
the survival rate in a group of patients from an oncology referral center in Mexico, all of them diagnosed with
ovarian carcinoma.
This retrospective study consisted of 1009 patients with EOC, diagnosed between 2006 and 2013 at the National
Cancerology Institute (Instituto Nacional de Cancerología-INCan), considering only those with CA125 measurements
before any chemotherapy or surgical cytoreduction. Patients with three years of medical follow-up having pretreatment
CA125 value and simultaneous diagnoses of histological subtype, clinical stage and differentiation grade of the tumor
(n = 656) were studied in order to determine their survival rate.
Results: The abnormal level (>35 U/mL) of CA125 was observed in 99 % of serous carcinoma cases rated I to IV in
the FIGO stages. Abnormal CA125 proportions were 89 % in endometrioid subtype and 69 % in mucinous tumors,
with the highest absolute value of CA125 observed in serous carcinoma surpassing any other histological subtype.
Clinical stages III and IV displayed increased CA125 values compared to stages I and II. Undifferentiated carcinomas
show the highest level of this indicator compared with those of low and moderate differentiated grade. Survival
evaluation by Kaplan-Meier analysis including only high grade serous carcinoma at FIGO stage III (n = 57)
demonstrated 57.1 % chances of survival in patients with CA125 pretreatment levels higher than 500 U/mL.
Survival was 26.7 % in patients with CA125 lower than 500 U/mL and the hazard ratio for CA125 ≤ 500 U/mL
was 2.28, 95 % CI 1.08–4.84, P = 0.032.
Conclusions: Clinical stage associated with pretreatment absolute values of CA125 should be considered as
prognostic factor in EOC patients. Values of CA125 higher than 500 U/mL in high grade serous carcinoma with
FIGO stage III resulted in an enhanced survival rate of the patients.
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Background
Description of the CA125 antigen determinant repre-
sents an important contribution to clinical management
of ovarian cancer patients. This glycoprotein recognized
by a murine monoclonal antibody (OC125) is codified
by MUC16 gene in the locus 19 p13, and is secreted by
coelomic derived epithelia [1–4]. Measurement of CA125
in serum are the preferential marker for epithelial ovarian
cancer, with CA125 levels higher than 35 U/mL being
considered abnormal and associated with 90 % of ovarian
carcinoma; levels of CA125 are useful to evaluate the
response to chemotherapy, relapse and progression of
the disease [5] and measurement of CA125 levels in the
screening of ovarian cancer in general population has
been largely evaluated [6, 7].
Serum levels of CA125 measured before any treatment
or debulking surgery have been evaluated as a reliable pre-
dictor of patient survival in epithelial ovarian cancer cases
[8]. However, results of initial CA125 levels in relation to
survival index are controversial because several variables
need to be considered [9]: for example, the percentage of
abnormal in CA125 serum levels values increases with the
clinical stage of the tumor, reaching to 98 % in FIGO stage
IV [4]. Similarly, changes have been observed depending
on the histological type of tumors [10].
The aim of this study was to examine the association
of pretreatment levels of serum CA125 with the clinical
stage, histology and differentiation grade of the tumor as
well as the prognostic impact in a group of patients di-
agnosed with epithelial ovarian cancer (EOC) from an
oncology referral center in Mexico.
Methods
This retrospective study comprised 1009 patients with
EOC, diagnosed between 2006 and 2013 at the National
Institute of Cancerology (Instituto Nacional de Cancero-
logía-INCan-008/034/OMI) in Mexico City. The protocol
of the study was approved by the Ethical Committees of
INCan and the School of Medicine of the National Au-
tonomous University of Mexico (Universidad Nacional
Autonoma de Mexico-UNAM-108/2015). Only patients
with CA125 measurements before any chemotherapy or
surgical cytoreduction were considered. Patients with pre-
treatment CA125 value and simultaneous diagnosis of
histological subtype, clinical stage and differentiation
grade of the tumor were analyzed (n = 656), with the clin-
ical stage, histological subtype and differentiation grade
being established according to FIGO and WHO criteria,
respectively [11]. Serum levels of CA125 were determined
by chemiluminescent enzyme immunoassay (Immunolite
OM-MA, Siemens Healthcare), considering CA125 values
higher than 35 U/mL as abnormal. Survival analyses
included patients with three years’ follow-up from the
date of diagnosis. The treatment of patients followed the
INCan protocol, including the use of cisplatin and
paclitaxel, with all patients being considered for over-
all survival evaluation notwithstanding the number of
chemotherapy cycles received.
Results
The contingency table with the proportion of normal
and abnormal CA125 was analyzed using Pearson’s chi-
squared test contrasting the proportions of the groups
by calculating “Z” value. Absolute values of CA125 U/
mL were normalized by expressing the values as natural
logarithms (LN), normal distribution of data was evalu-
ated by Kolgomorov Smirnov’s test and LN data were
analyzed by ANOVA with post-hoc Tukey’s test. The
survival rate was analyzed using the Kaplan-Meier
method and significance by means of log-rank testing.
The hazard ratio for CA125 grouped in two categories,
low level - 0–500 U/mL- and high level - > 500 U/mL.-,
was calculated in serous carcinoma using multivariate
Cox regression, the clinical stage and differentiation
grade values were considered as covariates. Hazard ratio
for the age of the patients has not been included, how-
ever, median age of both groups was similar, 53.4 and
53.8 years, respectively.
Significance was considered when the P ≤ 0.05. Ana-
lysis was performed using SAS version 9.1 (SAS Institute
Inc, Cary, NC).
Patients were referred from the whole country, mainly
from the central region of Mexico. The educational level
of the patients was elementary in three of four. The me-
dian age of the study population was 51, ranging from
18 to 90 years old; 60 % of the patients were aged 41–60
years. The mean body mass index of the patients was
26.8 Kg/m2, with 60 % of them undergoing menopause.
The following proportions of histological subtypes were
observed in epithelial ovarian cancer patients (n = 1009):
serous 55 %, endometrioid 19 %, mucinous 8 %, clear cells
8 %, and mixed carcinoma 10 %. The clinical stages of the
patients were stage III (42 %), stage IV (36 %) whereas
stages I and II represented the remaining 22 %.
Considering the degree of differentiation of tumoral
cells within the ovarian carcinoma cases studied, undif-
ferentiated carcinoma (G3) was the most frequently di-
agnosed (67 %), while the moderate differentiated (G2)
and well-differentiated (G1) varieties were observed in
17 % and 16 % of the patients, respectively.
Proportion of abnormal CA125 and malignant serum
values is indicated in Table 1: Results were grouped by
histological subtype and clinical FIGO stage. Analysis of
the contingency table indicated that percentage of ab-
normal CA125 levels changed in relation to histological
subtype and clinical stage.
Abnormal levels of CA125 were observed in 99 % of
serous carcinoma cases ranked from I to IV in their
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clinical stage progression. Patients with serous carcinoma
at clinical stage I displayed normal CA125 values in 11 %
of the cases, while in clinical stage IV, all patients with
serous subtype showed abnormal CA125 values.
The overall proportion of abnormal CA125 values
(stages I to IV) was 89 % in endometrioid subtype of
ovarian carcinoma, while patients with an endometrioid
carcinoma at FIGO stage I showed 19 % of normal
CA125 levels. Similarly to serous subtype, endometrioid
ovarian carcinoma displayed 100 % of abnormal CA125
at clinical stage IV.
Reduced proportion of abnormal levels is evident in
mucinous subtype ovarian cancer, where the increment
of CA125over 35 U/mL was observed in only 69 % of
the tumors. Interestingly, the proportion of abnormal
CA125 values did not increase in stage III and IV com-
pared to stage I.
Patients diagnosed with clear cells carcinoma displayed
an intermediate value between endometrioid and mucin-
ous subtypes, with 82 % of abnormal CA125 values at
stages I to IV, showing a significant increase between stage
I (67 %) and stages III and IV considered together (95 %).
Mixed carcinoma cases displayed similar values of
CA125 to those observed in serous and endometrioid
histological subtype. These tumors always include a
serous or endometriod component.
The mean serum values of CA125 expressed as U/mL
are indicated in Table 1 for each group, classifying the
absolute values of CA125 in four levels: 0–35, 35–100,
100–500 and >500 U/mL, CA125 correlated with histo-
logical subtype, clinical stage (p < 0.001) and differentiation
grade (p < 0.01). In order to perform an analysis of
variance, absolute values were converted to a natural
logarithm considering histological subtype, clinical
stage and differentiation grade. The highest value of
CA125 was observed in serous carcinoma compared to
any other histological subtype (Fig. 1a). Clinical stages
III and IV displayed increased CA125 values compared
to stages I and II (Fig. 1b). Undifferentiated carcinomas
show the highest level compared to low and moderate
differentiated grades (Fig. 1c).
Survival evaluation was performed by Kaplan-Meier
analysis including only high grade serous carcinoma at
FIGO stage III (n = 57). The comparison was done be-
tween low and high pretreatment level of CA125, 0–500
U/mL and more than 500 U/mL, respectively. Results
demonstrated a 57.1 % of survival after a three years
follow-up of patients with CA125 pretreatment levels
higher than 500 U/mL, and although the survival rate
was 26.7 % in patients with CA125 lower than 500 U/mL,
P = 0.027 (Fig. 2). This result was not observed when
selection was omitted and the whole population of
EOC was included in the analysis (data not shown).
The number of patients does not allow the separate
analysis of each carcinoma subtype.
The hazard ratio was calculated by means of the Cox
regression in patients diagnosed with serous carcinoma
(n = 85), considering the clinical stage (I to III) and the
differentiation grade (G1 to G3) as covariates, resulting
in two groups of CA125 values: ≤500 and > 500 U/mL
(referent). The result for CA125 ≤ 500 U/mL was HR
2.28, 95 % CI 1.08–4.84, P = 0.032.
Table 1 Pretreatment CA125 level >35 U/mL in epithelial ovarian cancer. Relationship between histological subtype and FIGO stage
Histological subtypes
FIGO Stage Serous Endometrioid Mucinous Clear Cell Mixed Total
I 8/9 30/37 16/22 12/18 9/10 75/96
89 % 81 % 73 % 67 % 90 % 78 %
231 U/mL 137 U/mL 113 U/mL 153 U/mL 305 U/mL
II 3/4 6/8 1/1 1/1 2/2 13/16
75 % 75 % 100 % 100 % 100 % 81 %
90 U/mL 281 U/mL 75 U/mL 1042 U/mL 252 U/mL
III 116/118 35/36* 6/10 11/11* 27/28 195/203
98 % 97 % 60 % 100 % 96 % 96 %
1255 U/mL 861 U/mL 195 U/mL 415 U/mL 1182 U/mL
IV 137/137* 13/13 4/6 7/8 10/10 171/174
100 % 100 % 67 % 88 % 100 % 98 %
2005 U/mL 511 U/mL 144 U/mL 376 U/mL 1240 U/mL
Total 264/268 84/94 27/39*** 31/38 48/50
99 % 89 % 69 % 82 % 96 %
Values indicate the proportion and percentage of patients with abnormal CA125 and the means of pretreatment values of CA125 U/mL. Comparison of
proportions (“Z”)
*P < 0.05 versus FIGO stage I; ***P < 0.001 vs serous and P < 0.01 vs. endometrioid total values
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Discussion
The patients included in this study constitute a repre-
sentative sample of the population of the middle region
of Mexico and can be considered as roughly similar to
the Hispanic population of the United States. All of
them came from the same hospital, which is a referral
public hospital specialized in oncology cases, and were
relatively homogenous in terms of social and economic
status. The protocol for diagnosis and treatment followed
was the same for all patients. The classification of histo-
logical subtype, clinical stage and differentiation grade
considered for this study was retrospectively obtained
from their clinical records. Measurements of pretreatment
serum CA125 were performed at the INCan laboratory or
validated there.
The obtained results demonstrated that serous carcin-
oma displays the highest frequency of abnormal values
increasing with the advanced clinical stages (III and IV).
Serum absolute values of CA125 increased up to tenfold
at FIGO stage IV compared to stage I. A similar obser-
vation was obtained in endometrioid carcinoma, with
significant low absolute values compared to serous sub-
type. Mucinous subtype showed abnormal values in
69 % at stage I carcinoma. These results confirm pre-
vious findings of several authors [4, 5, 9]. Interestingly,
in mucinous carcinoma no increase was observed in re-
lation to clinical stage neither in frequency of abnormal
values nor in absolute values of CA125. Observations
in mucinous carcinoma have not been explained. It is
possible that the secretion of various types of mucins
changes the relationship with the MUC16/CA125 expres-
sion. Alternatively, the origin of mucinous malignancy
explains variations in the behavior of this carcinoma.
Present results show an enhanced survival in patients
with high grade serous carcinoma (HGSC), FIGO stage
III and pretreatment serum CA125 level higher than 500
U/mL. These results have been observed when the pa-
tients were stratified; only HGSC, FIGO III patients were
considered for the Kaplan-Meier analysis. The stratified
analysis eliminates the influence of histological subtypes,
clinical stage and differentiation grade on CA125 levels;
this influence was corroborated in the present results. It
should be considered that results were obtained classify-
ing over and under 500 U/mL of CA125 serum levels.
When the entire cohort of EOC patients was included,
Kaplan-Meier analysis showed a poor survival in patients
with highest values of CA125, as previously reviewed [5].
Interestingly, a previous study of survival related to
WT1 expression in EOC evidenced contrasting changes
in the results, considering the entire cohort versus high
grade serous subtype in Kaplan-Meier analysis [12].
Similar finding to our results has been previously de-
scribed in patients stratified by CA125 serum level, the

































































Fig. 1 Absolute values of pretreatment CA125 normalized to natural
logarithms (LN). a Classified by histological subtypes. b Grouped
according to FIGO stage. c Separated by degree of differentiation.
Bars represent: Mean ± SD, n = as indicated in Table 1. Bars with
different superscript indicate P < 0.05
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in HR after Cox analysis [13]. Moreover, measuring
CA125 in tumor tissue, among late-stage ovarian cancer
patients a reduction of hazard ratio (HR = 0.63) has been
observed when tumor tissue displayed positive CA125
expression; a positive correlation was found between ele-
vated serum CA125 levels and elevated levels of CA125
tissue expression [14].
The hazard ratio (HR) obtained from Cox regression
coincides with Kaplan Meier results, showing an increase
of this indicator in patients with CA125 < 500 U/mL.
Present results indicate that a low level of pretreatment
CA125 in HGSC, FIGO stage III, although abnormal,
would have a poor prognostic. The explanation of these
results will require further studies; probably, patients with
a carcinoma generating high levels of CA125 react diffe-
rentially to disease or to treatment, resulting in an in-
creased survival rate. Present findings support the theory
that EOC is not a single entity, being at least five diseases
with different natural histories [15, 16].
Conclusions
It is important to consider that survival results were
obtained from the analysis of a stratified group. Clinical
stage associated with pretreatment absolute values of
CA125 should be considered a prognostic factor,
among others, in EOC patients. Values of CA125 higher
than 500 U/mL in high grade serous carcinoma with
FIGO stage III resulted in an enhanced survival rate of
the patients.
Abbreviations
EOC, epithelial ovarian cancer; FIGO, International Federation of Gynecology
and Obstetrics; HGSC, high grade serous carcinoma; INCan, National
Cancerology Institute; WHO, World Health Organization
Acknowledgements
The authors would like to express their gratitude to Abraham Ortiz, Nydia
Jaimes, Judith Naranjo, Karol Romero and Victor Olivares for their collaboration
in obtaining information from clinical reports and Alejandro Garzon for
reviewing the manuscript.
Funding
This work was supported by PAPIIT IN218213; PAPIIT IN224116 (DGAPA UNAM)
and INCan 080340MI.
Availability of data and materials
We can share the database information because we don’t have National
Cancer Institute authorization.
Authors’ contributions
FMV, CMH, EP, HNLB, conceived the study, analyzed and interpreted the
results and wrote the manuscript, EP, JR, carried out the statistical analysis
and MJG, SC, EC, RS, MA collected clinical information and built the
database. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Fig. 2 Kaplan-Meier analysis of pretreatment CA125 values separated in low (≤500 U/mL) and high (>500 U/mL) level in patients with high grade
serous carcinoma, FIGO stage III. P = 0.027 (Log- Rank test)
Morales-Vásquez et al. Journal of Ovarian Research  (2016) 9:41 Page 5 of 6
Consent for publication
Not Applicable.
Ethics approval and consent to participate
The protocol of the study was approved by the Ethical Committees of INCan
(008/034/OMI) and the School of Medicine of the National Autonomous
University of Mexico (Universidad Nacional Autonoma de Mexico- UNAM -
108/2015).
Author details
1Medical Oncology Department, National Cancerology Institute, Mexico City,
Mexico. 2Embryology Department, School of Medicine, National Autonomous
University of Mexico (Universidad Nacional Autonoma de Mexico-UNAM-),
Mexico City, Mexico. 3Public Health Department, School of Medicine,
National Autonomous University of Mexico (Universidad Nacional Autonoma
de Mexico-UNAM-), Mexico City, Mexico.
Received: 25 January 2016 Accepted: 17 June 2016
References
1. Bast Jr RC, Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC. Reactivity
of a monoclonal antibody with human ovarian carcinoma. J Clin Invest.
1981;68:1331–7.
2. Yin BW, Lloyd KO. Molecular cloning of the CA125 ovarian cancer antigen:
Identification as a new mucin, MUC16. J Biol Chem. 2001;276:27371–5.
3. Kabawat SE, Bast Jr RC, Bhan AK, Welch WR, Knapp RC, Colvin RB. Tissue
distribution of a coelomic-epithelium related antigen recognized by the
monoclonal antibody OC125. Int J Gynecol Pathol. 1983;2:275–85.
4. Jacobs I, Bast Jr RC. The CA 125 tumour-associated antigen: a review of the
literature. Hum Reprod. 1989;4:1–12.
5. Gupta D, Lis CG. Role of CA125 in predicting ovarian cancer survival - a
review of the epidemiological literature. J Ovarian Res. 2009;2:13.
6. Jacobs IJ, Skates SJ, MacDonald N, Menon U, Rosenthal AN, Davies AP, et al.
Screening for ovarian cancer: a pilot randomised controlled trial. Lancet.
1999;353:1207–10.
7. Menon U, Ryan A, Kalsi J, Gentry-Maharaj A, Dawnay A, Habib M, et al. Risk
algorithm using serial biomarker measurements doubles the number of
screen-detected cancers compared with a single-threshold rule in the
United Kingdom Collaborative Trial of Ovarian Cancer Screening. J Clin
Oncol. 2015;33:2062–71.
8. Felder M, Kapur A, Gonzalez-Bosquet J, Horibata S, Heintz J, Albrecht R, et al.
MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress.
Mol Cancer. 2014;13:129.
9. Zorn KK, Tian C, McGuire WP, Hoskins WJ, Markman M, Muggia FM, et al.
The prognostic value of pretreatment of CA 125 in patients with advanced
ovarian carcinoma: a Gynecologic Oncology Group study. Cancer. 2009;
115:1028–35.
10. de la Cuesta R, Maestro ML, Solana J, Vidart JA, Escudero M, Iglesias E, et al.
Tissue quantification of CA 125 in epithelial ovarian cancer. Int J Biol
Markers. 1999;14:106–14.
11. Tavassoli FA, Devilee P. World Health Organization Classification of Tumours.
Pathology and Genetics of Tumours of the Breast and Female Genital
Organs. Lyon: IARC Press; 2003.
12. Kobel M, Kalloger SE, Boyd N, McKinney S, Mehl E, Palmer C, et al. Ovarian
carcinoma subtypes are different diseases: implications for biomarker
studies. PLoS Med. 2008;5:e232.
13. Cooper BC, Sood AK, Davis CS, Ritchie JM, Sorosky JI, Anderson B, et al.
Preoperative CA 125 levels: an independent prognostic factor for epithelial
ovarian cancer. Obstet Gynecol. 2002;100:59–64.
14. Høgdall EV, Christensen L, Kjaer SK, Blaakaer J, Kjaerbye-Thygesen A, Gayther S,
et al. CA125: expression pattern, prognosis and correlation with serum CA125
in ovarian tumor patients: from the Danish “MALOVA” ovarian cancer study.
Gynecol Oncol. 2007;104:508–15.
15. Kurman RJ, Shih IM. The dualistic model of ovarian carcinogenesis: revisited,
revised, and expanded. Am J Pathol. 2016;186:733–47.
16. Prat J. Ovarian carcinomas: five distinct diseases with different origins,
genetic alterations, and clinico pathological features. Virchows Arch.
2012;460:237–49.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Morales-Vásquez et al. Journal of Ovarian Research  (2016) 9:41 Page 6 of 6
